Hodgkin's Disease Clinical Trials

A listing of Hodgkin's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
RADVAX FOR RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: A PHASE II TRIAL OF PEMBROLIZUMAB + LOW DOSE RADIOTHERAPY

We plan to treat subjects with pembrolizumab in combination with radiation therapy to see if the combination is an effective treatment for relapsed/refractory non-Hodgkin lymphoma.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

Non-Hodgkin lymphoma is a disease that can be treated effectively with chemotherapy and immunotherapy, but relapses can occur. The purpose of this study is to research the use of a new radioimmunotherapy drug called Betalutin®.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Phase I Trial of huCART19-IL18 Cells in Patients with Relapsed or Refractory CD19+ Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

0.0

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 11420: A Phase 1/2 Open-Label Clinical Trial of TC-110 T Cells in Adults With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL) Or Acute Lymphoblastic Leukemia (ALL)

8.0

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 03419: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkins Lymphoma

This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)

  • 0 views
  • 19 Feb, 2024
  • 1 location
RADVAX FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS

The long-term goal is to develop an effective regimen for r/r HL patients.

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 45418: An Open-Label Phase I/II Safety and Efficacy Study of Itacitinib in Combination with Everolimus in Subjects with Relapsed/Refractory Classical Hodgkin Lymphoma

The study will assess how safe and well-tolerated a combination of the study drugs itacitinib and everolimus in patients with Hodgkin lymphoma. We also hope to learn how effective this experimental combination is in treating Hodgkin lymphoma, when given together.

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).

  • 0 views
  • 19 Feb, 2024
  • 1 location
ConsCIOUS2: A Prospective Study of the Isolated Forearm Technique Commands Long-term Sequelae and Electroencephalograph Correlates Following Laryngoscopy and Intubation in patients 18 - 40 years of age

We will also collect routinely recorded clinical data to frame the observations about IFT responsiveness (please see list below and data collection form) and additionally collect non-invasive HD-EEG data to provide information about the brain state of the patients.

  • 0 views
  • 19 Feb, 2024
  • 1 location